ArriVent BioPharma, Inc.

AVBP

ArriVent BioPharma, Inc.

AVBP

Insider Sentiment (TTM):

Last Purchase:2024-01-30Last Sale:2025-12-10Shares Purchased (TTM):0Shares Sold (TTM):555,555

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:41,883,937Shares Outstanding:45,067,658Institutional Ownership Pct.:92.94%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	155	62	46	113	113	50	74	283	299	317
Short Term Investments	218	264	267	188	123	126	145	-	-	-
Prepaid Expense And Other Assets Current	21	22	20	21	14	10	8	10	10	10
Assets Current	394	349	333	321	250	186	227	292	309	327
Long Term Investments	-	-	-	5	19	29	48	-	-	-
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0
Deferred Costs	0	0	0	-	-	-	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0
Assets	395	349	333	327	270	215	275	293	309	328
Liabilities And Stockhold…
Liabilities
Liabilities Current
Accounts Payable Current	2	9	6	6	4	4	4	5	4	4
Accrued Liabilities Current	25	16	20	16	15	8	13	10	8	6
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0
Liabilities Current	28	25	26	22	20	13	17	15	12	10
Operating Lease Liability Noncurrent	0	0	-	-	-	-	0	0	0	0
Liabilities	28	25	26	22	20	13	17	15	12	10
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	865	772	712	674	584	505	496	495	494	493
Retained Earnings Accumulated Deficit	-498	-448	-405	-369	-334	-303	-238	-218	-197	-175
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	-0	-0	-	-	-
Stockholders Equity	367	324	307	305	250	203	258	277	297	318
Liabilities And Stockholders Equity	395	349	333	327	270	215	275	293	309	328
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0
Seriesa Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0
Series B Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	48	45	42	41	37	34	34	34	34	33
Shares Outstanding	48	45	42	41	37	34	34	34	34	33

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	4.58%	19.47%	5.65%	-	-	-	-	-	-	-	-	-
2025	17.66%	3.90%	-6.65%	16.10%	14.09%	7.71%	32.74%	11.83%	20.91%	-15.13%	20.48%	5.86%
2024	11.81%	6.85%	28.92%	16.95%	13.82%	28.52%	4.20%	-1.99%	1.64%	-13.98%	-5.49%	-7.40%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Liquidity Ratios
Current Ratio	14.16	13.95	12.83	14.90	12.74	14.34	13.14	19.28	25.50	32.82
Quick Ratio	13.40	13.06	12.06	13.93	12.00	13.59	12.67	18.66	24.69	31.81
Working Capital	366.33M	323.71M	306.95M	299.66M	230.51M	172.83M	209.71M	277.24M	296.41M	317.50M
Leverage & Debt
Debt to Equity	0.08	0.08	0.08	0.07	0.08	0.06	0.07	0.05	0.04	0.03
Debt Ratio	0.07	0.07	0.08	0.07	0.07	0.06	0.06	0.05	0.04	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-3.44	-3.22	-4.32	-3.61	-3.91	-3.76	-2.56	-	-	-
Free Cash Flow Per Share TTM	-3.66	-2.98	-4.18	-1.86	-1.67	-3.53	-2.23	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Growth Metrics
Net Income Growth (1Y)	19.53%	13.95%	106.62%	-	-	-	-	-	-	-
EPS Growth (1Y)	-12.11%	-14.29%	69.06%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-10.10	-7.16	-4.65	-5.11	-5.56	-4.92	-10.42	-	-	-
P/B TTM	4.51	3.21	2.52	2.54	3.05	3.09	3.25	2.84	2.09	1.41
Market Cap	1.65B	1.04B	773.87M	773.29M	762.08M	626.79M	838.34M	789.17M	621.47M	447.33M
Enterprise Value	1.50B	977.61M	728.33M	660.62M	649.32M	576.93M	764.05M	506.32M	322.80M	129.94M
Calculated Values
Free Cash Flow TTM	-174.05M	-134.47M	-160.59M	-78.07M	-58.62M	-119.59M	-70.21M	-	-	-
Net Debt	-154.68M	-62.10M	-45.54M	-112.67M	-112.77M	-49.87M	-74.29M	-282.86M	-298.67M	-317.39M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-10Sale

Owner: Hhlr, Advisors, Ltd., Hil…

Title: -

Shares: 555,555

Price/Share: $23.37

Value: $12,983,320.35

Shares Owned: 3,929,117

Relationship: TenPercentOwner

Ownership: Indirect

2024-01-30Purchase

Owner: Hhlr, Advisors, Ltd., Hil…

Title: -

Shares: 555,555

Price/Share: $18.00

Value: $9,999,990.00

Shares Owned: 4,484,672

Relationship: TenPercentOwner

Ownership: Indirect

2024-01-30Purchase

Owner: Orbimed, Asia Gp Iv, L.P.…

Title: -

Shares: 444,444

Price/Share: $18.00

Value: $7,999,992.00

Shares Owned: 1,513,664

Relationship: Director,TenPercentOwner

Ownership: Indirect

2024-01-30Purchase

Owner: Gordon, Carl L

Title: -

Shares: 444,444

Price/Share: $18.00

Value: $7,999,992.00

Shares Owned: 1,513,664

Relationship: Director,TenPercentOwner

Ownership: Indirect

2024-01-30Purchase

Owner: Healy, James

Title: -

Shares: 444,444

Price/Share: $18.00

Value: $7,999,992.00

Shares Owned: 1,696,752

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-10	Hhlr, Advisors, Ltd., Hil…	TenPercentOwner	-	Indirect	Sale	555,555	23.37	$12,983,320.35	3,929,117	4
2024-01-30	Hhlr, Advisors, Ltd., Hil…	TenPercentOwner	-	Indirect	Purchase	555,555	18.00	$9,999,990.00	4,484,672	4
2024-01-30	Orbimed, Asia Gp Iv, L.P.…	Director,TenPercentOwner	-	Indirect	Purchase	444,444	18.00	$7,999,992.00	1,513,664	4
2024-01-30	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Purchase	444,444	18.00	$7,999,992.00	1,513,664	4
2024-01-30	Healy, James	Director	-	Indirect	Purchase	444,444	18.00	$7,999,992.00	1,696,752	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.94%

Inst. Shares: 41,883,937

Shares Outstanding: 45,067,658

2025-12-31

103.93%

Inst. Shares: 39,973,271

Shares Outstanding: 38,462,600

2025-09-30

91.88%

Inst. Shares: 38,508,876

Shares Outstanding: 41,912,905

2025-06-30

95.34%

Inst. Shares: 33,375,167

Shares Outstanding: 35,006,114

2025-03-31

73.60%

Inst. Shares: 24,949,141

Shares Outstanding: 33,898,870

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	41,883,937	45,067,658	92.94%
2025-12-31	39,973,271	38,462,600	103.93%
2025-09-30	38,508,876	41,912,905	91.88%
2025-06-30	33,375,167	35,006,114	95.34%
2025-03-31	24,949,141	33,898,870	73.60%
2024-12-31	28,380,774	31,469,328	90.19%
2024-09-30	25,838,576	33,581,810	76.94%
2024-06-30	21,645,638	33,502,347	64.61%
2024-03-31	21,835,509	25,046,531	87.18%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ArriVent BioPharma, Inc. (AVBP) — SEC Financial Statements & Analysis

ArriVent BioPharma, Inc. (AVBP) is a pharmaceutical preparations company, incorporated in DE. ArriVent BioPharma, Inc. trades on Nasdaq as: AVBP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ArriVent BioPharma, Inc. reported a Debt-to-Equity ratio of 0.08x, a Price-to-Book (P/B) ratio of 4.51x (TTM), at a market cap of $1.65B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.08x
P/B TTM: 4.51x
Market Cap: $1.65B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ArriVent BioPharma, Inc. in?

ArriVent BioPharma, Inc. (AVBP) operates in the Pharmaceutical Preparations industry.

What is AVBP's market cap?

ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $1.65B as of 2026-06-30.

What exchange does AVBP trade on?

ArriVent BioPharma, Inc. (AVBP) trades on the Nasdaq.

Where is ArriVent BioPharma, Inc. incorporated?

ArriVent BioPharma, Inc. is incorporated in DE.